Denali Therapeutics Inc.
DNLI· Nasdaq
Released Nov 6, 2024, after the close
10-Q filed Nov 6, 2024, 37 days after period end · 0001714899-24-000216
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $1.27M | $184.00K | $5.29M |
| Net Income | -$107.19M | -$99.35M | -$103.30M | -$84.59M |
| EPS Diluted |
Denali Therapeutics Inc. · CIK 1714899 · Engraved from SEC EDGAR
| -$0.63 |
| -$0.72 |
| -$0.84 |
| -$0.69 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.